Why the study?
What are the regional differences in the prescription of antithrombotic therapy for stroke prevention in patients newly diagnosed with atrial fibrillation?
Population
15,092 patients newly diagnosed with non-valvular atrial fibrillation at risk for stroke
Design
Cohort
Authors
Loading...
Regional OAC disparities in new AF persist despite NOAC uptake; leaves open drivers of under-treatment in Asia.
What are the regional differences in the prescription of antithrombotic therapy for stroke prevention in patients newly diagnosed with atrial fibrillation?
There are substantial geographic variations in antithrombotic therapy for atrial fibrillation, with NOACs driving high overall OAC use globally, though significant under-treatment persists in certain regions like Asia and among high-risk patients.
Mazurek et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: